Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.

Expert review of anticancer therapy - 1 Dec 2019

Blakely Collin M, Riess Jonathan W

Abstract excerpt

Introduction: Lung cancer is the leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. The continued advancement of DNA sequencing technology and the discovery of multiple specific driver mutations underlying many cases of NSCLC are moving clinical intervention toward a more targeted approach. Here we focus on anaplastic lymphoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to Gene Rearrangement

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Sulfones

Source

Identifiers

PMID: 31809604
DOI: 10.1080/14737140.2019.1699792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.PMID 31809604Read ↗

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Semantic proximity Read ↗

Unraveling the Potential of ALK-Targeted Therapies in NSCLC: Comprehensive Insights and Future DirectionsSemantic proximity Read ↗

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Semantic proximity Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

Ceritinib for ALK-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.